C5U

dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate


Toggle HydrogenToggle Labels

Chemical Component Summary

Namedimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Identifiersdimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
FormulaC17 H18 N2 O6
Molecular Weight346.335
TypeNON-POLYMER
Isomeric SMILESCC1=C(C(C(=C(N1)C)C(=O)OC)c2ccccc2N(=O)=O)C(=O)OC
InChIInChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count0
Bond Count44
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB01115 
NameNifedipine
Groups approved
DescriptionNifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
Synonyms
  • 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
  • Nifedipino
  • Nifedipine
  • Nifedipinum
Brand Names
  • Taro-nifedipine Cap 10mg
  • Nifedipine Pa 20 - Srt 20mg
  • Nifedipine ER
  • Procardia
  • NIFEdipine
IndicationNifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.[L11383] Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.[L11389,L1245]
Categories
  • Agents causing hyperkalemia
  • Antiarrhythmic agents
  • Antihypertensive Agents
  • Antihypertensive Agents Indicated for Hypertension
  • Beta blocking agents and calcium channel blockers
ATC-Code
  • C08CA55
  • C08GA01
  • C08CA05
  • C07FB03
CAS number21829-25-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Voltage-dependent L-type calcium channel subunit alpha-1CMVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAAL...unknowninhibitor
Voltage-dependent L-type calcium channel subunit alpha-1DMMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTV...unknowninhibitor
Voltage-dependent L-type calcium channel subunit beta-2MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKN...unknowninhibitor
Nuclear receptor subfamily 1 group I member 2MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG...unknownagonist
CalmodulinMADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQ...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL193
PubChem 4485
ChEMBL CHEMBL193
ChEBI CHEBI:7565
CCDC/CSD BICCIZ05, BICCIZ14, BICCIZ12, ASATOD, JENMUN01, SUZGEA, BICCIZ13, BICCIZ02, BICCIZ06, BICCIZ07, QUPRUP, BICCIZ03, JENMUN, JENMOH, BICCIZ09, BICCIZ, BICCIZ04, BICCIZ15, WEKDUP